INTERIM REPORT JANUARY - DECEMBER 2011
The January–December period and the fourth quarter 2011 in brief · Net sales amounted to MSEK 0.0 (0.0) · Net loss was MSEK 226.6 (163.5), whereof the fourth quarter MSEK 50.6 (50.1) · Loss per share was SEK 0.59 (0.67), whereof the fourth quarter SEK 0.13 (0.20) · Cash flow from operating activities was MSEK -198.3 (-158.9), whereof the fourth quarter MSEK -37.9 (-44.3). The increase in the full year primarily concerns costs related to the phase III program for eprotirome. · Cash and cash equivalents and other short-term investments totaled MSEK 158.5 (395.0) at the end of